The Journal of dermatology
Real-World Safety Profile of Spesolimab in Generalized Pustular Psoriasis: Insights From Japan as Part of a Multinational Expanded Access Program (EAP).
Akimichi Morita, Yayoi Tada, Yuichiro Tsunemi, Mayumi Komine, Takuro Kanekura, Shinichi Imafuku, Toshiya Takahashi, Xuemei Ding, Nichiren Pillai, Morihisa Saitoh, Rafael Sani Simoes, Nora Pöntynen, Keiichi Yamanaka
Published: 202510.1111/1346-8138.70122
Abstract
Generalized pustular psoriasis (GPP) is a heterogeneous, systemic neutrophilic inflammatory disease, characterized by chronic symptoms and recurrent flares, which can be potentially life-threatening. Spesolimab, an interleukin-36 receptor antagonist,…
Preview only. Read the full abstract at the source